ID19623A - Antagonis reseptor vitronektin - Google Patents
Antagonis reseptor vitronektinInfo
- Publication number
- ID19623A ID19623A IDP973335A ID973335A ID19623A ID 19623 A ID19623 A ID 19623A ID P973335 A IDP973335 A ID P973335A ID 973335 A ID973335 A ID 973335A ID 19623 A ID19623 A ID 19623A
- Authority
- ID
- Indonesia
- Prior art keywords
- vitronektin
- receptor antagonists
- antagonists
- receptor
- vitronektin receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2732096P | 1996-10-02 | 1996-10-02 | |
| US4377697P | 1997-04-11 | 1997-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ID19623A true ID19623A (id) | 1998-07-23 |
Family
ID=26702318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IDP973335A ID19623A (id) | 1996-10-02 | 1997-10-01 | Antagonis reseptor vitronektin |
Country Status (37)
| Country | Link |
|---|---|
| EP (1) | EP0957917B1 (xx) |
| JP (2) | JP4491072B2 (xx) |
| KR (1) | KR100589578B1 (xx) |
| CN (1) | CN1114403C (xx) |
| AP (1) | AP1463A (xx) |
| AR (1) | AR008878A1 (xx) |
| AT (1) | ATE312089T1 (xx) |
| AU (1) | AU733417B2 (xx) |
| BG (1) | BG64581B1 (xx) |
| BR (1) | BR9712248B1 (xx) |
| CA (1) | CA2267224C (xx) |
| CO (1) | CO4900046A1 (xx) |
| CY (1) | CY2576B1 (xx) |
| CZ (1) | CZ299076B6 (xx) |
| DE (1) | DE69734833T2 (xx) |
| DK (1) | DK0957917T3 (xx) |
| DZ (1) | DZ2320A1 (xx) |
| EA (1) | EA002419B1 (xx) |
| ES (1) | ES2252775T3 (xx) |
| HK (1) | HK1023730A1 (xx) |
| HU (1) | HU229221B1 (xx) |
| ID (1) | ID19623A (xx) |
| IL (1) | IL129243A (xx) |
| MA (1) | MA24361A1 (xx) |
| MY (1) | MY137606A (xx) |
| NO (1) | NO320194B1 (xx) |
| NZ (1) | NZ334953A (xx) |
| PE (1) | PE10499A1 (xx) |
| PL (1) | PL190859B1 (xx) |
| RO (1) | RO119881B1 (xx) |
| SA (1) | SA98180936B1 (xx) |
| SK (1) | SK285029B6 (xx) |
| TR (1) | TR199900737T2 (xx) |
| TW (1) | TW487702B (xx) |
| UA (1) | UA60311C2 (xx) |
| UY (2) | UY24735A1 (xx) |
| WO (1) | WO1998014192A1 (xx) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
| TW527355B (en) | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
| WO1999015170A1 (en) * | 1997-09-24 | 1999-04-01 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
| CA2304000A1 (en) * | 1997-09-24 | 1999-04-01 | William E. Bondinell | Vitronectin receptor antagonist |
| US6372719B1 (en) | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| JP2002533387A (ja) * | 1998-12-23 | 2002-10-08 | ジー．ディー．サール ＆ カンパニー | 腫瘍治療の複合療法としてインテグリン拮抗物質と一つ以上の抗腫瘍剤を使用する方法 |
| EP1150965A4 (en) * | 1999-02-03 | 2002-05-15 | Merck & Co Inc | BENZAZEPINE DERIVATIVES FOR USE AS ANTAGONISTS OF THE INTEGRIN ALPHA-V RECEPTOR |
| JP5127096B2 (ja) * | 1999-04-30 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用 |
| AU6523200A (en) * | 1999-08-06 | 2001-03-05 | Smithkline Beecham Corporation | Vitronectin receptor antagonists useful for the treatment of strokes |
| US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| DE10028575A1 (de) | 2000-06-14 | 2002-03-14 | Basf Ag | Integrinliganden |
| DE10027514A1 (de) * | 2000-06-06 | 2002-01-03 | Basf Ag | Liganden von Integrinrezeptoren |
| FR2806082B1 (fr) * | 2000-03-07 | 2002-05-17 | Adir | Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| KR100854424B1 (ko) | 2001-01-29 | 2008-08-27 | 3-디멘져널 파마슈티칼즈 인코오포레이티드 | 치환된 인돌 및 인테그린 길항제로서의 이들의 용도 |
| ES2319877T3 (es) * | 2001-04-10 | 2009-05-14 | Smithkline Beecham Corporation | Metodo para inhibir la formacion de adherencias. |
| SE0101386D0 (sv) | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | New compounds |
| US7109191B2 (en) | 2001-05-03 | 2006-09-19 | Merck & Co., Inc. | Benzazepinone alpha vintegrin receptor antagonists |
| WO2003059251A2 (en) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Antibody targeting compounds |
| GB0215867D0 (en) * | 2002-07-09 | 2002-08-14 | Glaxosmithkline Spa | Novel method and compounds |
| EP1628949A4 (en) * | 2003-04-04 | 2008-07-02 | Smithkline Beecham Corp | PROCESS AND INTERMEDIATE PRODUCTS FOR PREPARING BENZAZEPINES |
| JP5223072B2 (ja) * | 2004-04-02 | 2013-06-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ａｖβ５インテグリンに関連のある疾患を治療および予防するための方法および組成物 |
| AU2012216372B2 (en) * | 2004-04-02 | 2015-01-22 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| UA87854C2 (xx) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-бензил)-2-фенілбутанаміди як модулятори рецептора андрогену$n-(2-бензил)-2-фенилбутанамиды как модуляторы рецептора андрогена |
| WO2006069079A2 (en) * | 2004-12-21 | 2006-06-29 | Smithkline Beecham Corporation | Methods and formulations |
| PL1968594T3 (pl) * | 2005-11-29 | 2011-03-31 | Glaxosmithkline Llc | Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki |
| EP2217238B1 (en) | 2007-11-08 | 2014-03-12 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| CA2705916C (en) * | 2007-11-16 | 2016-01-05 | Ube Industries, Ltd. | Benzazepinone compound |
| WO2009111679A2 (en) * | 2008-03-06 | 2009-09-11 | Smithkline Beecham Corporation | Process |
| WO2010093706A2 (en) | 2009-02-10 | 2010-08-19 | The Scripps Research Institute | Chemically programmed vaccination |
| US20120095215A1 (en) * | 2009-03-30 | 2012-04-19 | Ube Industries, Ltd. | Medical composition for treatment or prophylaxis of eye diseases |
| JP5572996B2 (ja) * | 2009-05-15 | 2014-08-20 | 宇部興産株式会社 | ベンズアゼピノン化合物を有効成分として含有する医薬 |
| AU2010275367B2 (en) | 2009-07-24 | 2015-09-03 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with avB5 integrin |
| JP5856063B2 (ja) | 2009-11-17 | 2016-02-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物 |
| EP2325194A1 (en) * | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
| EP3148587B1 (en) | 2014-05-30 | 2021-02-24 | Pfizer Inc | Carbonitrile derivatives as selective androgen receptor modulators |
| BR112022021228A2 (pt) * | 2020-04-26 | 2022-12-06 | Jiangsu Nhwa Pharmaceutical Co Ltd | Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2197160T3 (es) * | 1992-12-21 | 2004-01-01 | Smithkline Beecham Corp | Antagonistas fibronogeno bicicliclos. |
| AU702661B2 (en) * | 1994-06-29 | 1999-02-25 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| ZA955391B (en) * | 1994-06-29 | 1996-02-09 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| JPH10504825A (ja) * | 1994-08-22 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | 二環式化合物 |
| WO1996026190A1 (en) * | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
-
1997
- 1997-01-10 UA UA99031739A patent/UA60311C2/uk unknown
- 1997-09-29 DZ DZ970170A patent/DZ2320A1/xx active
- 1997-09-30 MA MA24817A patent/MA24361A1/fr unknown
- 1997-09-30 MY MYPI97004552A patent/MY137606A/en unknown
- 1997-10-01 ES ES97909979T patent/ES2252775T3/es not_active Expired - Lifetime
- 1997-10-01 DK DK97909979T patent/DK0957917T3/da active
- 1997-10-01 KR KR1019997002811A patent/KR100589578B1/ko not_active IP Right Cessation
- 1997-10-01 PE PE1997000876A patent/PE10499A1/es not_active Application Discontinuation
- 1997-10-01 PL PL332674A patent/PL190859B1/pl unknown
- 1997-10-01 DE DE69734833T patent/DE69734833T2/de not_active Expired - Lifetime
- 1997-10-01 SK SK425-99A patent/SK285029B6/sk not_active IP Right Cessation
- 1997-10-01 EA EA199900356A patent/EA002419B1/ru not_active IP Right Cessation
- 1997-10-01 AP APAP/P/1999/001493A patent/AP1463A/en active
- 1997-10-01 EP EP97909979A patent/EP0957917B1/en not_active Expired - Lifetime
- 1997-10-01 ID IDP973335A patent/ID19623A/id unknown
- 1997-10-01 WO PCT/US1997/018001 patent/WO1998014192A1/en active IP Right Grant
- 1997-10-01 CN CN97180168A patent/CN1114403C/zh not_active Expired - Fee Related
- 1997-10-01 JP JP51694298A patent/JP4491072B2/ja not_active Expired - Fee Related
- 1997-10-01 HU HU9903769A patent/HU229221B1/hu not_active IP Right Cessation
- 1997-10-01 CA CA002267224A patent/CA2267224C/en not_active Expired - Fee Related
- 1997-10-01 RO RO99-00353A patent/RO119881B1/ro unknown
- 1997-10-01 CZ CZ0113299A patent/CZ299076B6/cs not_active IP Right Cessation
- 1997-10-01 BR BRPI9712248-3A patent/BR9712248B1/pt not_active IP Right Cessation
- 1997-10-01 UY UY24735A patent/UY24735A1/es not_active IP Right Cessation
- 1997-10-01 AT AT97909979T patent/ATE312089T1/de active
- 1997-10-01 AU AU47462/97A patent/AU733417B2/en not_active Ceased
- 1997-10-01 NZ NZ334953A patent/NZ334953A/xx not_active IP Right Cessation
- 1997-10-01 CO CO97057225A patent/CO4900046A1/es unknown
- 1997-10-01 IL IL12924397A patent/IL129243A/en not_active IP Right Cessation
- 1997-10-01 TR TR1999/00737T patent/TR199900737T2/xx unknown
- 1997-10-02 AR ARP970104549A patent/AR008878A1/es active IP Right Grant
-
1998
- 1998-02-10 TW TW086114545A patent/TW487702B/zh not_active IP Right Cessation
- 1998-03-01 SA SA98180936A patent/SA98180936B1/ar unknown
- 1998-03-25 UY UY24935A patent/UY24935A1/es not_active IP Right Cessation
-
1999
- 1999-03-31 NO NO19991590A patent/NO320194B1/no not_active IP Right Cessation
- 1999-03-31 BG BG103299A patent/BG64581B1/bg unknown
-
2000
- 2000-05-22 HK HK00103033A patent/HK1023730A1/xx not_active IP Right Cessation
-
2007
- 2007-05-18 CY CY0700010A patent/CY2576B1/xx unknown
-
2009
- 2009-10-09 JP JP2009235447A patent/JP2010006838A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ID19623A (id) | Antagonis reseptor vitronektin | |
| DE69812096D1 (de) | Neuropeptid y rezeptorantagonisten | |
| NO972016D0 (no) | Indolyl-Y-reseptorantagonister | |
| ID18003A (id) | Antagonis muskarinik | |
| ID16742A (id) | Antagonis reseptor endotelin | |
| DK1009732T3 (da) | 1-Amino-alkylcyclohexan NMDA receptor antagonister | |
| ATE315035T1 (de) | Ccr-3-rezeptor-antagonisten | |
| NO951613D0 (no) | Ikke-peptidyl tachykinin reseptorantagonister | |
| NO20012411D0 (no) | Pyrrolidin-derivater-CCR-3-reseptorantagonister | |
| EP0912175A4 (en) | FIBRINOGENIC RECEPTOR ANTAGONISTS | |
| ATE280157T1 (de) | 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii | |
| EP0885205A4 (en) | FIBRINOGENIC RECEPTOR ANTAGONISTS | |
| ID24726A (id) | Antagonis-antagonis reseptor trombin | |
| EP0885213A4 (en) | FIBRINOGEN RECEPTOR ANTAGONISTS | |
| ID26223A (id) | Antagonis reseptor vitronektin | |
| NO950606D0 (no) | Adhesjonsreseptor-antagonister | |
| ID24162A (id) | Antagonis-antagonis reseptor vitronektin | |
| DK0906294T3 (da) | Benzoxazinon-dopamin D4-receptor-antagonister | |
| ID28811A (id) | Antagonis reseptor vitronektin | |
| ID24468A (id) | 2-asilaminopropanamina sebagai antagonis reseptor tachykinin | |
| TR199501389A2 (tr) | Adesyon reseptörü antagonistleri (karsitlari). | |
| DE69616364D1 (de) | Endothelinrezeptorantagonisten | |
| ID24309A (id) | 2-asilaminopropanamina sebagai antagonis reseptor tachykinin | |
| ID22978A (id) | Antagonis reseptor endotelin | |
| TR199601082A3 (tr) | Entegrin reseptör antagonistleri. |